Conceptual Approach to CAD Risk. Disclosures. Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management 2/10/2014.

Similar documents
Who Cares About the Past?

Khurram Nasir, MD MPH

Are We Ready for a Paradigm Shift From Risk Factors to Detection of Subclinical Coronary Atherosclerosis? Lessons From MESA. Khurram Nasir, MD MPH

Imaging-Guided Statin Allocation: Seeing Is Believing

Using Coronary Artery Calcium Score in the Quest for Cardiac Health. Robert J. Hage, D.O.

New Paradigms in Predicting CVD Risk

Preclinical Detection of CAD: Is it worth the effort? Michael H. Crawford, MD

Case Discussions: Treatment Strategies for High Risk Populations. Most Common Reasons for Referral to the Baylor Lipid Clinic

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

Review of guidelines for management of dyslipidemia in diabetic patients

Are Lipids (or Risk Factors) the Optimal Marker for ASCVD Risk Assessment? Time for Paradigm Shift? Franklin D. Roosevelt. Khurram Nasir, MD MPH

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Financial Disclosures. Coronary Artery Calcification. Objectives. Coronary Artery Calcium 6/6/2018. Heart Disease Statistics At-a-Glace 2017

ACC/AHA GUIDELINES ON LIPIDS AND PCSK9 INHIBITORS

Current Cholesterol Guidelines and Treatment of Residual Risk COPYRIGHT. J. Peter Oettgen, MD

Lipid Management: The Next Level How Will the New ACC/AHA Guidelines Change My Practice

Colin Edwards Cardiologist Waitemata Health and Auckland Heart Group

The Art of Cardiovascular Risk Assessment

Cardiac CT for Risk Assessment: Do we need to look beyond Coronary Artery Calcification

Disclosures. Objectives. Cardiovascular Risk. Patient Case. JUPITER: The final frontier in statin utilization or an idea from outer space?

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

American Osteopathic College of Occupational and Preventive Medicine 2012 Mid-Year Educational Conference St. Petersburg, Florida

Assessing atherosclerotic risk for long term preventive treatment

Learning Objectives. Patient Case

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

Combining Coronary Artery Calcium Scanning with SPECT/PET Myocardial Perfusion Imaging

Hyperlipidemia. Intern Immersion Block 2015

Low-density lipoproteins cause atherosclerotic cardiovascular disease (ASCVD) 1. Evidence from genetic, epidemiologic and clinical studies

1. Which one of the following patients does not need to be screened for hyperlipidemia:

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Coronary Artery Calcification

Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis

4/14/2018 DYSLIPIDEMIA CASES. Mary Malloy, MD. I have nothing to disclose

9/3/ AHA/ACC Lipid Guidelines on the Treatment of Cholesterol to Reduce Atherosclerosis. Disclosure

Lipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:

Lipid Management 2013 Statin Benefit Groups

Update on Cholesterol Management: The 2013 ACC/AHA Guidelines

40% minimum reduction from

Disclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Coronary Artery Calcium. Vimal Ramjee, MD FACC The Chattanooga Heart Institute

Review current guideline recommendations for lipid-lowering therapy

Short and Long Term Prognosis after Coronary Artery Calcium Scoring

Prevention of Heart Disease: The New Guidelines

Dyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram

NEW GUIDELINES FOR CHOLESTEROL

CT Calcium Score and Statins in Primary CV Prevention. Dr Selwyn Wong

Risk Factors for Heart Disease

Subclinical atherosclerosis in CVD: Risk stratification & management Raul Santos, MD

David Ramenofsky, MD Bryan Kestenbaum, MD

Lipoprotein Particle Profile

Is Universal Pediatric Lipid Screening Justified? YES. Damon Dixon, MD, FAAP Preventative Cardiology March 7 th, 2016

No relevant financial relationships

CVD risk assessment using risk scores in primary and secondary prevention

Disclosures CORONARY CALCIUM SCORING REVISITED. Learning Objectives. Scoring Methods. Consultant for M2S, Inc. Coronary Calcium Scoring: Software

Contemporary management of Dyslipidemia

Polish Your Practice Heart Failure. Why Prevent Vs. Treat? Coronary Heart Disease. A Challenging Patient:1994. Risk Factors for Heart Attack

Pathophysiology of Lipid Disorders

Cardiovascular Risk Assessment Using Risk Scores in Primary Prevention. Khurram Nasir, MD MPH

Cardiac CT Angiography

Page 1. Disclosures. Background. No disclosures

Cardiometabolics in Children or Lipidology for Kids. Stanley J Goldberg MD Diplomate: American Board of Clinical Lipidology Tucson, Az

Defining Severe Familial Hypercholesterolemia. Raul D. Santos MD, PhD Brazil

Beyond Framingham: Risk Assessment & Treatment for Primary Prevention

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

Coronary Artery Calcium Scoring Mirvat Alasnag FACP, FRCP, FSCCT, FSCAI, FASE King Fahd Armed Forces Hospital, Jeddah. March 2017

Title for Paragraph Format Slide

DYSLIPIDEMIA TREATMENT: HYBRIDIZING CLINICAL PRACTICE GUIDELINES

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

Cardiovascular Disease Prevention: Current Knowledge, Future Directions

Disclosures. Prevention of Heart Disease: The New Guidelines. Summary of Talk. Four guidelines. No relevant disclosures.

COURAGE to Leave Diseased Arteries Alone

Low HDL-levels: leave it or treat it?

Lipid Control Today: Management within the Context of other Cardiovascular Risk Factors

Life Science Journal 2018;15(12)

Supplementary Online Content

Case Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer

How would you manage Ms. Gold

Lipids: Translating Studies into Practice. WD04: Cortney Joneikis, MD, MS Bob Gleeson, MD Jeff Whittle, MD, MPH

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

Beyond Framingham. Prediction of cardiovascular risk. Niels van Pelt Cardiologist, Middlemore Hospital

EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Atherosclerotic Disease Risk Score

Potential recommendations for CT coronary angiography in athletes

Testing the Asymptomatic CAD Patient: When and Why?

10/8/2015. MN Nursing Conference October 7th, 2015 Michael Miedema, MD MPH. None

Spotty Calcification as a Marker of Accelerated Progression of Coronary Atherosclerosis : Insights from Serial Intravascular Ultrasound

Placebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN

Lipids What s new (and what s not)

Lipids What s new? Meera Jain, MD Providence Portland Medical Center

Latest Guidelines for Lipid Management

Lp(a) Ready for prime time? E Stroes AMC

LDL cholesterol (p = 0.40). However, higher levels of HDL cholesterol (> or =1.5 mmol/l [60 mg/dl]) were associated with less progression of CAC

HYPERLIPIDEMIA Liz Grant, MD. UNM Department of Family and Community Medicine July 2012

Implementation of CV Risk and. Dyslipidemia Guidelines. Impact on Americans 11/25/2014. Summary Implementing new. Dyslipidemia Guidelines

Transcription:

Integrating Imaging and Biomarkers for Optimal CVD Risk Assessment and Management None Disclosures Arthur Agatston Conceptual Approach to CAD Risk Devereux Circulation, 1993 1

Age Obesity Family Hx Diabetes Hypertension Thrombogenic RFs Obesity Diabetes Hypertension LDL CAC Tobacco LDL Family History Tobacco HDL 9p21 Fitness Microbiome HDL 9p21 Fitness Microbiome (Carnitine) Unknown Unknown Impact of coronary artery calcium on coronary heart disease events in individuals at the extremes of traditional risk factor burden: the Multi-Ethnic Study of Atherosclerosis The New Prevention Strategy Known Family History Life Style Pre-Clinical Disease Silverman, MG. European Heart Journal December 23, 2013 Unknown 2

AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04 Family History Known Life Style Pre-Clinical Disease Framingham Risk Score Unknown AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04 FRS-Low Family History Known Life Style Pre-Clinical Disease AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04? Lp(a) Blocked arteries->bypass Surgery Calcium Score>1500 Unknown 3

AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04 Family History Known Life Style Clinical Disease AG-High Risk with Zero Risk Factors Risk of Heart Attack Calcium Score Unknown Lp(a),?HDL Dysfunction Number of (RF) Nasir K, Circ Cardiovasc Imaging. 2012; 5:467-473 PS 70 F TC=314,LDL=229 Known PS-The Power of Zero (MESA) Family History Life Style Calcium Score=0 Pre-Clinical Disease Unknown? Martin SA, Circulation. 2014;129:77-86 4

PS 70 yo TC=314,LDL=229 Calcium Score=0, Large LDL Why FH and 0 CAC?? Large LDL Particles CAC in Familial Hypercholesterolemia n=107, 45+/-13, 36% DMW 56M CAC=750 age 44 +++ FH: father MI/CABG at 50, Brother MI age 50 CACS=1,386 1/11/08; CACS=1,000, 90th% 11/8/05 @ Baptist; CACS=750.9 8/31/01 per EBT; M.H. Miname et al. Atherosclerosis 213 (2010) 486 491 CAC: 1/11/08 11/8/05 8/31/01 1,386 1,000 750 5

High LDL, High CAC (MESA) CAC in Familial Hypercholesterolemia n=107, 45+/-13, 36% Martin SA, Circulation. 2014;129:77-86 M.H. Miname et al. Atherosclerosis 213 (2010) 486 491 SS 70 M, DM, BP, BMI 27, TC, +FH,Low HDL, high TG, small LDL Diabetic, High Cholesterol, Multiple How to Treat? + Diabetes 6

Risk of Heart Attack SS-CAC=0 The Power of Zero Calcium Score CAC Score Groups Diabetes & no CAC Is Rx indicated? No MetS/DM (n= 4036 ) MetS without DM (n =1687) DM (n=882 ) CHD Event rate per 1000 Person Year 0 0.7 (0.3-1.4) 1.2 (0.5-2.8) 1.6 (0.5-5.1) 1-99 3.3 (2.1-5.2) 6.1 (3.7-9.9) 9.1 (5.0-16.4) 100-399 6.0 (3.7-9.9) 12.6 (7.9-20.0) 13.4 (7.4-24.2) Number of (RF) Nasir K, Circ Cardiovasc Imaging. 2012; 5:467-473 400+ 12.0 (7.7-18.6) 15.3 (9.1-25.8) 18.3 (10.9-30.9) Malik S, Budoff M, Katz R, Blementhal RJ, Alain Bertoni, Blumenthal RS, Nasirk K, Szklo M, Barr G, Wong ND ( Diabetes Care 2012) AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04? Blocked arteries->bypass Surgery Calcium Score>1500 Why?? HDL Dysfunction 7

LDLR Cholesterol Pool HDL Metabolism Liver LDL/VLDL CETP HDL 2 ABCA1 NL Function HDL GGE (80 yo WF with Calcium Score=0) Apo A1 SRB1 HDL 3 ABCA1 Plaque Down Regulated ABCA1 Too Much HDL3 Liver HDL 2 ABCA1 SRB1 HDL 3 ABCA1 8

HDL Size Distribution Spectrum Healthy Un Healthy HDL Dysfunction Treatment BP-69 yo F- +FH No other known risk factors 4/17/00 4/16/01 TCS=1766 Stent Stent TG=142 HDL=120 LDL=100 LDL-S=267 Lp(a)=10 FRS=1%? Rx SRB1 Dysfunctional HDL-2 SRB-1 Model LDLR LDL/VLDL CETP Liver HDL 2 ABCA1 HDL 3 ABCA1 9

HDL GGE in SRB1/CETP Downregulation (HDL2 Bump) BP-69 yo F- +FH No other known risk factors 4/17/00 4/16/01 TCS=1766 Stent Stent TG=142 HDL=120 LDL=100 LDL-S=267 Lp(a)=10 FRS=1%? Rx BP-69 yo HDL 120, Low FRS, + FH BP Family (father 84-CAC 121-33 rd %) HDL GGE -2000 BP-69F CAC~1800 HDL=120 SP-54M CAC=443 HDL=87 JP-47 CAC=596 HDL=113 10

M-T Family-father MI 42 JT-59F-CAC=2,267 HDL=144 JT-59F-CAC=2,267 HDL=144 JM-58M-CAC=494 HDL=88 GM 55M CAC=1,154 HDL=102 JT-59F-CAC=2,267 HDL=144 HDL Bump LDL Bump AG, 54 yo WM Police Major +FH CAD Competitive Runner TC=180 TG= 64 HDL=58 LDL=109 CRP=.04 Calcium Score>1500 11

LW 64 WF-DM1-CAC=3,000 Father MI ~43 LW 64 WF-DM1-CAC=3,000 LW 64 WF-DM1-CAC=3,000 HDL in Type 1 Diabetes Epidemiology of Diabetes Complications Study Costacou, T, J Clin Lipidology 2011; 5:387-394 12

Familial HDL Dysfunction Established Clinical CAD/Carotid Calcium Score > 75 th percentile Family h/o Premature CAD Low Risk Framingham Score Normal BMI Normal Insulin Sensitivity Elevated or Normal HDL/TG < 100 HDL 2 Bump NL LDL PPD/Small LDL Bump The Future of Coronary Imaging There is a lot more clinical information in CT and CTA Images Natural History of Atherosclerotic Plaque Natural History of the Post Rupture Lesions Fibrous tissue Calcium Old Young 13

Calcium Density of Coronary Artery Plaque and Risk of Incident Cardiovascular Events Old Young Youngest Younger MH Criqui, MJ Budoff,JAMA. 2014;311(3):271-278. Steady Athero Progression Arrested Progression due to Rx 100 20 Individual Plaque Score 5 0 100 20 Individual Plaque Score 5 0 14

SJ 70 F 2ppd smoker d/ced age 48 CAC-280 JCC-61: cac=79 belly fat resolved 20 yrs ago Late Onset due to Weight Gain Metabolic Syndrome or Young Patient AF 73 M CAC=274, from low score age 63 MS->DM2 x 10 yrs 100 20 Individual Plaque Score 5 0 15

Young, Thrombogenic Event 100 20 Individual Plaque Score 5 0 Devereux Circulation, 1993 PQ Thank You 16

Most People who Develop Heart Attacks have Normal LDL Values Heart attack with normal LDL Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines Of 136,905 patients hospitalized with CAD, more than 75% had LDL levels below 130 mg/dl 23% had LDL-C <70 mg/dl 2011 CGHDI Sachdevaet al. AHJ, Vol 157, 111-117 Jan 2009 Framingham-Total Cholesterol to HDL Ratio in those with and without future heart attacks AG-High Risk with Zero Risk Factors Lloyd-Jones DM, Arch Intern Med 2001;161:949-954 Silverman, MG. European Heart Journal December 23, 2013 17